文献速递神经乳腺技术与安全MR

新型高弛豫率二聚体大环钆螯合物在神经与肿瘤病变临床前模型中的效能

Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies.
PubMed 文献 · Invest Radiol · 2026-03-23

本研究在胶质瘤、脑膜瘤、缺血和乳腺腺癌共112只动物模型中评估新型二聚体大环钆对比剂digadoglucitol的成像效能。结果显示,半剂量digadoglucitol的信号增强和对比噪声比与标准剂量钆特酸葡甲胺及钆布醇相当,全标准剂量则优于后两者,提示其有望在维持或提高诊断准确性的同时降低剂量。

要点

  • 半剂量digadoglucitol(0.05 mmol Gd/kg)的信号增强和CNR与0.1 mmol Gd/kg的钆特酸葡甲胺及钆布醇相当。
  • 全标准剂量digadoglucitol(0.1 mmol Gd/kg)的信号增强和CNR超过钆特酸葡甲胺和钆布醇。
  • 四种病理模型(胶质瘤、脑膜瘤、缺血、乳腺腺癌)均被准确定位,各组体积一致。

核心结论

  • Digadoglucitol在神经与肿瘤疾病临床前模型中显示高诊断效能,半剂量时效果与现有GBCAs相当,全标准剂量时对比增强更优,作者认为其是有望进入临床转化的对比剂,可能实现降低剂量并维持或提高诊断准确性。

研究设计与样本

  • 临床前动物实验,纳入胶质瘤、脑膜瘤、缺血和乳腺腺癌模型共112只动物,digadoglucitol给药剂量为0.1 mmol Gd/kg和0.05 mmol Gd/kg,钆特酸葡甲胺和钆布醇给药剂量为0.1 mmol Gd/kg,MRI评估给药前后信号增强和对比噪声比(CNR),以组织学分析(苏木精-伊红染色及既定病理标准)确认肿瘤恶性程度和缺血病灶。

关键影像表现/征象

  • 所有病理模型均被准确定位,各治疗组体积一致。
  • 半剂量和全剂量digadoglucitol在胶质瘤、脑膜瘤、缺血和乳腺模型中均产生显著信号增强和CNR。
  • 增强和CNR值在半剂量时与钆特酸葡甲胺和钆布醇相当,在全剂量时超过后两者。

诊断标准与关键数值

  • 半剂量digadoglucitol(0.05 mmol Gd/kg)的信号增强和CNR与0.1 mmol Gd/kg的钆特酸葡甲胺及钆布醇相当。
  • 全标准剂量digadoglucitol(0.1 mmol Gd/kg)的信号增强和CNR超过0.1 mmol Gd/kg的钆特酸葡甲胺和钆布醇。
  • 肿瘤恶性程度和缺血病灶经苏木精-伊红染色及既定病理标准确认。

临床应用与阅片要点

  • 作者认为digadoglucitol是有望考虑用于临床转化的对比剂,可能允许降低剂量而维持或提高诊断准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Gadolinium-based contrast agents (GBCAs) are crucial for enhancing MRI contrast, especially in neurological and oncological imaging. Achieving high relaxivity is a primary focus in contrast media research. Recently, digadoglucitol, the first dimeric macrocyclic gadolinium complex, was introduced, offering significantly higher relaxivity compared with first-generation commercial macrocyclic GBCAs.

PURPOSE: This study assesses the performance of digadoglucitol in preclinical models of neurological and oncological diseases. It explores whether digadoglucitol provides comparable diagnostic efficacy at half the dose and superior contrast enhancement at the full standard dose compared with gadoterate meglumine and gadobutrol.

MATERIAL AND METHODS: All animal experiments and preclinical procedures adhered to national and international regulations. The study involved models of glioma, meningioma, ischemia, and breast adenocarcinoma, for a total of 112 animals. Digadoglucitol was administered at doses of 0.1 mmol Gd/kg and 0.05 mmol Gd/kg, whereas gadoterate meglumine and gadobutrol were given at 0.1 mmol Gd/kg. MRI sessions assessed signal enhancement and contrast-to-noise ratio (CNR) before and after contrast-agent administration.

RESULTS: All pathologic models were accurately localized with consistent volumes across treatment groups. Tumour malignancy and ischemic lesions were confirmed by histologic analysis using standard haematoxylin-eosin staining and established pathologic criteria. Quantitative analysis revealed that both half and full doses of digadoglucitol produced significant signal enhancement and CNR in glioma, meningioma, ischemia, and breast models. The enhancement and CNR values were comparable (at half-dose) or exceeded (at full-dose) those achieved with gadoterate meglumine and gadobutrol. Statistical analysis confirmed the significance of these results.

CONCLUSION: Digadoglucitol shows high diagnostic efficacy in preclinical models of neurological and oncological diseases. It delivers comparable effectiveness at half the dose and superior contrast enhancement at the full standard dose compared with established GBCAs. These preclinical findings suggest that digadoglucitol is a promising contrast agent to be considered for clinical translation, potentially allowing for reduced dosage while maintaining or improving diagnostic accuracy.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. La Cava F, Colombo Serra S, Cordaro A, et al. Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies. Invest Radiol. 2026. PMID: 41866988. doi:10.1097/RLI.0000000000001287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。